CA-DEXERIALS
22.3.2024 02:31:27 CET | Business Wire | Press release
Dexerials Corporation, (TOKYO: 4980) (Headquarters: Shimotsuke-shi, Tochigi, Representative Director and President: Yoshihisa Shinya, hereinafter “Dexerials”), which provides leading-edge technologies, materials, and devices for smartphones, automobiles, and other products, announces that the name of the integrated company to be created under Dexerials Precision Components Corporation (Headquarters: Tome-shi, Miyagi, Hereinafter “DXPC”) and Kyoto Semiconductor Co., Ltd. (Headquarters: Shimotsuke-shi, Tochigi, hereinafter “Kyoto Semiconductor”) has been determined as Dexerials Photonics Solutions Corporation (hereinafter “DXPS”), a consolidated subsidiary of Dexerials in Japan, and that DXPS will commence operation on April 1, 2024. In accordance with Dexerials’ news release on July 31, 2023, entitled Notice Regarding Launch of Integrated Company to Lead Growth in the Photonics Domain, preparations for a launch of the integrated company between DXPC and Kyoto Semiconductor had been made.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240321222931/en/
Change in sales structure after the launch of DXPS (Graphic: Business Wire)
The profile of DXPS is as follows.
Profile of the integrated company
Corporate name |
Dexerials Photonics Solutions Corporation |
Head office |
Shimotsuke-shi, Tochigi |
Offices |
Eniwa Operation, Kamisunagawa Operation and Tome Operation |
Date of inauguration |
April 1, 2024 |
Share capital |
100 million yen |
Representative (planned) |
Kazuya Hayashibe, Representative Director and President |
Business |
Development, production and production management of optical semiconductors, optical devices and semiconductor-composite devices (photonics products) |
Dexerials Group will support DXPS in developing and providing solutions essential to the evolution of technologies in the photonics domain, aiming to increase efficiency in society. In so doing, the Group will help build a sustainable society, while aiming to achieve continuous growth and higher corporate value.
DXPS will develop and manufacture** microdevices and optical semiconductor device products that have been operated by DXPC and Kyoto Semiconductor. Dexerials will sell them to customers as its photonics products.
Dexerials and Kyoto Semiconductor will participate as an exhibitor at the OFC 2024 trade show that will take place at the San Diego Convention Center in San Diego in the United States from Tuesday, March 26 to Thursday, March 28. We cordially invite visitors to the exhibition to drop by our booth.
Comment from Kazuya Hayashibe, Representative Director and President (planned), DXPS
The Dexerials Group has been effectively combining technologies with the knowledge possessed by its human resources to offer materials and solutions indispensable to electronics and automobiles, aiming to link them to the evolution of digital technologies.
In the future, artificial intelligence (AI), Internet of things (IoT), next-generation communication and other new technologies will have increasing opportunities to play significant roles in boosting the efficiency of society for solving social issues. It is hence anticipated that optical semiconductors and the photonics solutions that support them will also have greater roles to play.
DXPS will lead the Dexerials Group’s business growth in the photonics domain. It will combine the optical semiconductor technologies cultivated by Kyoto Semiconductor, one of its predecessors, with the Dexerials Group’s technologies of controlling light and electricity to create unprecedented photonics solutions and to help resolve social issues. This will be the reason for its existence and it will tackle its work with a strong determination.
Dexerials and Kyoto Semiconductor will showcase their products and present the integrated company, DXPS, in their booth at the OFC 2024 exhibition that will start on March 26 in San Diego in the United States. We cordially invite visitors to the exhibition to drop by our booth. We look forward to seeing you at San Diego.
Change in sales structure after the launch of DXPS
Please see the diagram.
(Notes) |
* DXPC, Kyoto Semiconductor and DXPS are wholly owned subsidiaries of Dexerials Corporation. |
|
** After the launch of DXPS, OSDC will continue to manufacture microdevices under contract. |
|
*** Photonics products correspond to products that have been handled by DXPC and Kyoto Semiconductor. |
Participation in the OFC 2024 exhibition in San Diego, USA
OFC 2024 Exhibition
Date: Tuesday, March 26, 2024 to Thursday, March 28, 2024
Venue: San Diego Convention Center (San Diego, USA)
Stand number: 3814
Official website: https://www.ofcconference.org/en-us/home/
Products to be displayed
1. Optical semiconductor
2. Inorganic waveplate
3. Smart precision Adhesive
4. Anisotropic Conductive Film (ACF)
About Dexerials Corporation https://www.dexerials.jp/en/
Dexerials Corporation is a manufacturer providing functional materials for use in smartphones, automobiles and other domains in accordance with its corporate vision, Value Matters - Unprecedented innovation, unprecedented value. On a global scale, Dexerials Corporation manufactures and markets Anisotropic Conductive Film (ACF), optical elastic resin (SVR), anti-reflection film, surface mounted type fuses, industrial adhesives, double- and single-sided tapes and other electronic parts, junction materials, optical materials, and many other materials.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240321222931/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom